Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objective: The tumor microenvironment has ample impact on the behavior of the malignant process in colon cancer (CC). Patients with a high percentage of stroma within the primary tumor, determined by the tumor-stroma ratio (TSR), have a poor prognosis. In metastatic lymph nodes from patients with stage III CC, the TSR is heterogeneous, but the impact on patients’ prognosis is unknown. Methods: Haematoxylin and eosin stained tissue slides of primary tumor (PT) and associated lymph nodes (LNs) metastases from 102 patients with stage III CC were analyzed for the TSR. Stroma-high (>50% stroma) and stromalow (≤ 50% stroma) groups were evaluated with respect to disease free survival (DFS). Results: Of 102 analyzed primary tumors, 47 (46.1%) scored as stroma-high and 55 (53.9%) as stroma-low. In total, 33 patients had at least one stroma-high LN and 69 patients had one or more stroma-low LNs. Interestingly, 28 patients (27.5%) had both stroma-high and stroma-low LNs, but in another 44 cases the TSR between PT and LNs differed: 29 patients had a stroma-high PT with stroma-low LNs, while 15 patients displayed the opposite. As a result of the combination of the TSR analysis of the PT and the involved metastatic LNs, 62 patients (60.8%) were classified as stroma-high and 40 (39.2%) as stroma-low, restaging 14.7% of the patients to stroma-high with a significantly worse 5-year DFS compared to stroma-low patients (59% vs. 82%, HR=2.83 (95%CI 1.34–5.97), P=0.006). In multivariate analysis, the TSR retained its independent prognostic impact (HR=2.85 (95%CI 1.33-6.10), P=0.007). Conclusion: The presence of abundant stroma in metastatic LNs from patients with stage III CC adds to the prognostic information learned from the primary tumor independently, and supports selective patient treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Sadanandam, A., Lyssiotis, C. A., Homicsko, K., Collisson, E. A., Gibb, W. J., Wullschleger, S., Ostos, L. C. G., Lannon, W. A., Grotzinger, C., Del Rio, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3175 · Cited by 960
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892 · cited 1×
“Moreover, recently identified mechanisms of therapeutic resistance, which were mainly conferred by changes in the tumor microenvironment, indicate the importance of the development of therapies targeting the non-cancer stromal cells, like fibroblasts and extracellular matrix components [24].”
BackgroundDe Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771 · cited 1×
“New colorectal cancer (CRC) subtypes have been identified by three independent research groups [20-22].”
BackgroundStromal contribution to the colorectal cancer transcriptome
Isella, C., Terrasi, A., Bellomo, S. E., Petti, C., Galatola, G., Muratore, A., Mellano, A., Senetta, R., Cassenti, A., Sonetto, C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3224 · Cited by 640 · cited 1×
“All groups identified one subtype associated with poor prognosis, and more importantly, this subtype was recently observed to associate with a high stromal content [23].”
BackgroundBaldus, S. E., Schaefer, K.-L., Engers, R., Hartleb, D., Stoecklein, N. H., & Gabbert, H. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2446 · Cited by 432
Mesker, W. E., Junggeburt, J. M. C., Szuhai, K., de Heer, P., Morreau, H., Tanke, H. J., & Tollenaar, R. A. E. M. (2007) · Analytical Cellular Pathology · doi:10.1155/2007/175276 · Cited by 354
Self-citation
Cited by
Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
van Pelt, G. W., Kjær-Frifeldt, S., van Krieken, J. H. J. M., Al Dieri, R., Morreau, H., Tollenaar, R. A. E. M., Sørensen, F. B., & Mesker, W. E. (2018) · Virchows Archiv · doi:10.1007/s00428-018-2408-z · Cited by 192
Self-citationThe tumour–stroma ratio in colon cancer: the biological role and its prognostic impact
van Pelt, G. W., Sandberg, T. P., Morreau, H., Gelderblom, H., van Krieken, J. H. J. M., Tollenaar, R. A. E. M., & Mesker, W. E. (2018) · Histopathology · doi:10.1111/his.13489 · Cited by 155
Self-citationPolack, M., Smit, M. A., van Pelt, G. W., Roodvoets, A. G. H., Meershoek-Klein Kranenbarg, E., Putter, H., Gelderblom, H., Crobach, A. S. L. P., Terpstra, V., Petrushevska, G., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102988 · Cited by 30
“34,35 Even small lymph nodes (cid”
Self-citationStrous, M. T. A., Faes, T. K. E., Gubbels, A. L. H. M., van der Linden, R. L. A., Mesker, W. E., Bosscha, K., Bronkhorst, C. M., Janssen-Heijnen, M. L. G., Vogelaar, F. J., & de Bruïne, A. P. (2022) · Clinical and Translational Oncology · doi:10.1007/s12094-021-02746-y · Cited by 20
Self-citation
Metadata
- Authors
- van Pelt, G. W., Hansen, T. F., Bastiaannet, E., Frifeldt, S. K., van Krieken, J. H. J., AEM Tollenaar, R., Sorensen, F. B., & Mesker, W. E.
- Venue
- Journal of Medical & Surgical Pathology
- Publisher
- OMICS Publishing Group
- Published
- 2016
- Volume
- 01
- Issue
- 02
- ISSN
- 2472-4971 (ISSN-L)
- OpenAlex
- W2527686267
- Cited by
- 24
- References
- 7
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.